Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA

Liao, Xuejiao1; Guan, Yuan1,2; Asakawa, Tetsuya1; Lin, Zixun1; Tang, Qingrong3; Ma, Zhenghua1; Wu, Shuting1; Wang, Xiaobin1; Dong, Jingke1; Zhang, Liping1; Deng, Jiayu1; Liao, Zhonghui1,4; Yang, Sumei1,4; Wang, Cheng1,4; Song, Shuo1; Yi, Hongyang1; Wu, Song5,7; Lu, Hongzhou1,6

2023

10.2147/IDR.S421380

INFECTION AND DRUG RESISTANCE   影响因子和分区

1178-6973

Purpose: The purpose was to review relevant clinical data and formulate recommendations supporting the use of saline as a simple rinse for an early reassuring intervention to reduce the occurrence of re-positive COVID-19 patients.Methods: We conducted a single-centre retrospective cohort study, which enrolled patients with confirmed re-testing positive COVID-19 during 7-60 days after discharge from Third People's Hospital of Shenzhen. By one-to-two propensity score matching for age and sex, the control group of those not re-testing positive during the same period served as matched control.Results: A total of 223 patients were included in our study, 94 in re-positive group and 129 in non-re-positive group. The result shows that the rates of nasal douche treatment in the non-re-positive group were considerably higher than that of the re-positive group. And the Ct value of nasal douche group increased faster than that of non-nasal douche group after the Ct value reaching >35. Further analysis revealed that the higher the Ct value at the time of readmission, the shorter the time of average Ct values to reach >35. Conclusion: These findings suggest that nasal douche is beneficial to shorten the time of virus nucleic acid turning negative, thereby reducing the incidence of re-positive. The prevention and control of epidemics focuses on re-positive patients with Ct values <35.

COVID-19 nasal douche re-positive RT-PCR

SCI

英语

第一 ; 通讯

Shenzhen Science and Technological Foundation["JCYJ20210324115611032","JSGG20220226090002003","JSGG20220301090005007"] ; Shenzhen High-level Hospital Construction Fund["G2021027","G2022062"] ; CAMS Innovation Fund for Medical Sciences[2022-I2M-CT-B-113]

Infectious Diseases ; Pharmacology & Pharmacy

Infectious Diseases ; Pharmacology & Pharmacy

WOS:001080997000001

DOVE MEDICAL PRESS LTD

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis,Inst Hepatol, Shenzhen, Peoples R China
2.Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China
3.First Hosp Changsha, Infect Dis Dept, Changsha, Peoples R China
4.Bengbu Med Coll, Sch Publ Hlth, Bengbu, Peoples R China
5.Shenzhen Univ, South China Hosp, Med Sch, Dept Cent Lab, Shenzhen, Peoples R China
6.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Hosp 2,Sch Med,Inst Hepatol, 29 Bulan Rd, Shenzhen 518112, Guangdong, Peoples R China
7.Shenzhen Univ, South China Hosp, Med Sch, Dept Cent Lab, 3688 Nanhai Dadao, Shenzhen 518060, Peoples R China

Liao, Xuejiao,Guan, Yuan,Asakawa, Tetsuya,et al. Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA[J]. INFECTION AND DRUG RESISTANCE,2023,16.

Liao, Xuejiao.,Guan, Yuan.,Asakawa, Tetsuya.,Lin, Zixun.,Tang, Qingrong.,...&Lu, Hongzhou.(2023).Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA.INFECTION AND DRUG RESISTANCE,16.

Liao, Xuejiao,et al."Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA".INFECTION AND DRUG RESISTANCE 16(2023).